Experiences with
Acute leukaemia1,922 public posts
Webinar 3.30pm, Tuesday 6th April - Acute lymphoblastic leukaemia (ALL) treatment update
Please join us for the 3rd in the series of acute leukaemia treatment updates.
This webinar will update on how ALL is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.
Please join us for the 3rd in the series of acute leukaemia treatment updates.
This webinar will update on how ALL is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.

Webinar 3.30pm, Thursday 11th March - Acute myeloid leukaemia (AML) treatment update
Please join us for our 2nd webinar in the acute leukaemia treatment updates series.
This webinar will update on how AML is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.
Please join us for our 2nd webinar in the acute leukaemia treatment updates series.
This webinar will update on how AML is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.

Webinar 9.30am, Wednesday 3rd March - Acute promyelocytic leukaemia (APL) treatment update
Please join us for the 1st in our series of free treatment updates in acute leukaemia.
This webinar will update on how APL is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.
Please join us for the 1st in our series of free treatment updates in acute leukaemia.
This webinar will update on how APL is treated today and what is on the horizon: how is a therapy chosen, how is prognosis determined and what level of involvement should patients expect in their care decisions.

Want to take advantage of all our features? Just log in!
or
Wednesday 13th January 2021 Webinar- Survivorship and late effects of acute leukaemia
Date: Wednesday 13th January 2021
Time: 9:30am
Guests:
Dr Amit Patel, Consultant Haematologist, Cellular Therapies and Transplantation, The Christie NHS Foundation Trust
Dr Steven Knapper, Clinical Senior Lecturer in Haematology and consultant haematologist, University Hospital of Wales.
Kate Stallard
Date: Wednesday 13th January 2021
Time: 9:30am
Guests:
Dr Amit Patel, Consultant Haematologist, Cellular Therapies and Transplantation, The Christie NHS Foundation Trust
Dr Steven Knapper, Clinical Senior Lecturer in Haematology and consultant haematologist, University Hospital of Wales.
Kate Stallard

Join us this morning at 11am for the launch or the Acute Myeloid Leukaemia (AML) North of England Virtual Support Group
10th August at 11am – Launch meeting – Hosted by Jessica Turner, Leukaemia Care North-West Regional Coordinator.
Our Acute Myeloid Leukaemia (AML) North Virtual Support Group is for anyone who has been diagnosed with AML in the North of England.
10th August at 11am – Launch meeting – Hosted by Jessica Turner, Leukaemia Care North-West Regional Coordinator.
Our Acute Myeloid Leukaemia (AML) North Virtual Support Group is for anyone who has been diagnosed with AML in the North of England.

Webinar - Coronavirus and acute leukaemia
Dr Patel will discuss the potential changes to your care as a result of the coronavirus outbreak as well as providing advice on living with acute leukaemia at this time.
Weds 8th April 10.15am
Register here https://zoom.us/webinar/register/WN_KeFZJqvmSZ6UEkVptgaaQw
Dr Patel will discuss the potential changes to your care as a result of the coronavirus outbreak as well as providing advice on living with acute leukaemia at this time.
Weds 8th April 10.15am
Register here https://zoom.us/webinar/register/WN_KeFZJqvmSZ6UEkVptgaaQw

Videos now available - Webinar talks and Q&A sessions - leukaemia and COVID - 19
These webinars on acute leukaemia and chronic lymphocytic leukaemia (CLL) can now be found on our YouTube >
In the videos leading consultants are joined by patients as they discuss and answer questions about how COVID-19 is affecting leukaemia patients.
These webinars on acute leukaemia and chronic lymphocytic leukaemia (CLL) can now be found on our YouTube >
In the videos leading consultants are joined by patients as they discuss and answer questions about how COVID-19 is affecting leukaemia patients.

Join us tomorrow at 4.00pm 5th August for the launch of the AML Virtual Support Group (South UK)
Our friendly virtual support group is open to anybody from the south of the UK that has been affected by a acute myeloid leukaemia diagnosis. This is a great opportunity to meet new people and share in real time your experiences.
Our friendly virtual support group is open to anybody from the south of the UK that has been affected by a acute myeloid leukaemia diagnosis. This is a great opportunity to meet new people and share in real time your experiences.

WEBINAR - Immunisations and living with the challenges of a compromised immune system – “top tips for staying safe”
University of Birmingham and Queen Elizabeth Hospital, Birmingham
Gillian Marshall, Haematology CNS at Queen Elizabeth Hospital, Birmingham
Samantha Slaney, acute myeloid leukaemia (AML) patient
Nick York, chronic lymphocytic leukaemia (CLL) patient and Patient Advocacy Healthcare Liaison Officer
University of Birmingham and Queen Elizabeth Hospital, Birmingham
Gillian Marshall, Haematology CNS at Queen Elizabeth Hospital, Birmingham
Samantha Slaney, acute myeloid leukaemia (AML) patient
Nick York, chronic lymphocytic leukaemia (CLL) patient and Patient Advocacy Healthcare Liaison Officer

Reminder 3.30pm Monday WEBINAR - Immunisations and living with the challenges of a compromised immune system – “top tips for staying safe”
University of Birmingham and Queen Elizabeth Hospital, Birmingham
Gillian Marshall, Haematology CNS at Queen Elizabeth Hospital, Birmingham
Samantha Slaney, acute myeloid leukaemia (AML) patient
Nick York, chronic lymphocytic leukaemia (CLL) patient and Patient Advocacy Healthcare Liaison Officer
University of Birmingham and Queen Elizabeth Hospital, Birmingham
Gillian Marshall, Haematology CNS at Queen Elizabeth Hospital, Birmingham
Samantha Slaney, acute myeloid leukaemia (AML) patient
Nick York, chronic lymphocytic leukaemia (CLL) patient and Patient Advocacy Healthcare Liaison Officer

Video Interview: Acute lymphoblastic leukaemia (ALL) research updates from ASH 2019. How genetic information aids diagnosis and treatment
Whilst there, the team spoke to a number of experts, in these first two videos we hear from Professor Anthony Moorman on how genetic information about the leukaemia cell is used in the diagnosis and treatment of acute leukaemia, along with what research was presented on the topic of genetics and acute
Whilst there, the team spoke to a number of experts, in these first two videos we hear from Professor Anthony Moorman on how genetic information about the leukaemia cell is used in the diagnosis and treatment of acute leukaemia, along with what research was presented on the topic of genetics and acute

Childhood ALL video update by Dr Sara Ghorashian from the 2019 American Society of Hematology (ASH)
In this video interview Dr Sara Ghorashian describes the remaining challenges in the treatment of childhood acute lymphoblastic leukaemia (ALL), and how these could be addressed. https://youtu.be/o4R9V5OeQoU
In this video interview Dr Sara Ghorashian describes the remaining challenges in the treatment of childhood acute lymphoblastic leukaemia (ALL), and how these could be addressed. https://youtu.be/o4R9V5OeQoU

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia
In approx. 15-20% of SWEET'S SYNDROME patients, their condition can be triggered by CANCER, one of the commonest being myelodyplastic syndromes which can progress to acute myeloid leukaemia.
In approx. 15-20% of SWEET'S SYNDROME patients, their condition can be triggered by CANCER, one of the commonest being myelodyplastic syndromes which can progress to acute myeloid leukaemia.

Filter results
Posted in
Sort by